Daniel J. George, MD

Daniel J. George, MD, is the Eleanor Easley Distinguished Professor, a professor of medicine, a professor in urology, and a professor in surgery at the Duke University School of Medicine and a member of the Duke Cancer Institute.

Articles

Overcoming Barriers to Cabazitaxel and Optimizing Sequencing

November 14th 2025

Evidence-based approaches to cabazitaxel use in mCRPC, addressing treatment sequencing after prior therapies, real-world underutilization trends, patient counseling on benefits and risks, and FDA guidance on dosing strategies to optimize outcomes while managing toxicity.

The Role of Chemotherapy in Today’s mCRPC Landscape

November 14th 2025

Evolution of chemotherapy's role in metastatic castration-resistant prostate cancer treatment, including its positioning relative to ARPIs, PARP inhibitors, and targeted therapies, with discussion of treatment sequencing strategies and practical considerations for docetaxel use in high-volume versus low-volume disease.

Dr George on the Role of Radioligand Therapy in Prostate Cancer Management

November 12th 2025

Daniel J. George, MD, discusses the potential of radioligand therapies for patients with prostate cancer and the evolution of this treatment paradigm.

Ongoing Research to Watch in Prostate Cancer in 2025 and Beyond

March 13th 2025

Daniel J. George, MD, and Matthew Smith, MD, PhD, discuss ongoing research to watch in prostate cancer.

Key Prostate Cancer Updates to Emerge From ASCO GU 2025

March 13th 2025

Daniel J. George, MD, and Matthew Smith, MD, PhD, discuss other key prostate cancer data presented at ASCO GU 2025.

Findings From a Real-World Analysis of ARPIs in Nonmetastatic CRPC

March 13th 2025

Daniel J. George, MD, and Matthew Smith, MD, PhD, discuss data from a real-world analysis for AR inhibitors in nmCRPC.

Outcomes by Disease Volume: A Subgroup Analysis of the ARANOTE Trial in mHSPC

March 12th 2025

Daniel J. George, MD, and Matthew Smith, MD, PhD, discuss a subgroup analysis from the ARANOTE trial in prostate cancer.

Data From an Age-Related Subgroup Analysis of the ARASENS Trial in mHSPC

March 12th 2025

Daniel J. George, MD, and Matthew Smith, MD, PhD, discuss an age-based subgroup analysis from the ARASENS trial in prostate cancer.

The Evolution of Treatment in Metastatic Hormone-Sensitive Prostate Cancer

March 12th 2025

Daniel J. George, MD, and Matthew Smith, MD, PhD, discuss the evolution of treatment for metastatic hormone-sensitive prostate cancer.

Dr. George on the Importance of Understanding Mutations in Prostate Cancer

December 14th 2022

Daniel J. George, MD, discusses the importance of understanding mutations in prostate cancer.

Dr. George on the Use of Niraparib for Patients With BRCA and ATM Mutations in mCRPC

December 9th 2022

Daniel J. George, MD, discusses the use of niraparib for patients with metastatic castration-resistant prostate cancer harboring BRCA and ATM mutations.

Dr. George on the Changing Treatment Landscape in Prostate Cancer

October 23rd 2019

Daniel J. George, MD, discusses the changing treatment landscape in prostate cancer.

Dr. George on Investigational Agents Downstream of the Androgen Receptor in Prostate Cancer

October 17th 2019

Daniel J. George, MD, discusses investigational agents downstream of the androgen receptor in advanced prostate cancer.

Dr. George on the Use of Radium-223 in Prostate Cancer

September 18th 2019

Daniel J. George, MD, professor of medicine and surgery, member, Duke Cancer Institute, discusses the use of radium-223 dichloride (Xofigo) in prostate cancer.

Dr. George on Promise of PARP Inhibitors in Prostate Cancer

August 9th 2019

Daniel J. George, MD, professor of Medicine and Surgery, member, Duke Cancer Institute, discusses the promise of PARP inhibitors in prostate cancer.

Dr. George Discusses Next Steps in RCC

April 10th 2019

Daniel J. George, MD, professor of Medicine and Surgery, member, Duke Cancer Institute, discusses next steps for research in renal cell carcinoma (RCC).

Dr. George on the Impact of Immunotherapy on TKIs in RCC

April 3rd 2019

Daniel J. George, MD, professor of medicine and surgery, member, Duke Cancer Institute, discusses the impact of immunotherapy on TKIs in renal cell carcinoma (RCC).

Dr. George on Dosing TKIs in RCC

March 20th 2019

Daniel J. George, MD, professor of Medicine and Surgery, member, Duke Cancer Institute, discusses the importance of dosing TKIs properly in patients with renal cell carcinoma (RCC).

Dr. George on Sequential Therapy in Metastatic Prostate Cancer

February 15th 2019

Daniel J. George, MD, professor of Medicine and Surgery, member, Duke Cancer Institute, discusses sequential therapy in metastatic prostate cancer.

Dr. George on Concerns With Immune-Related Adverse Events in RCC

January 10th 2019

Daniel J. George, MD, professor of Medicine and Surgery, member, Duke Cancer Institute, discusses concerns with immune-related adverse events (irAEs) in renal cell carcinoma (RCC).